105 related articles for article (PubMed ID: 13678316)
1. Phosphate prodrugs of isophosphoramide mustard.
Misiura K; Szymanowicz D; Wietrzyk J; Opolski A
Acta Pol Pharm; 2003; 60(2):109-12. PubMed ID: 13678316
[TBL] [Abstract][Full Text] [Related]
2. Isophosphoramide mustard analogues as prodrugs for anticancer gene-directed enzyme-prodrug therapy (GDEPT).
Misiura K; Szymanowicz D; Kuśnierczyk H; Wietrzyk J; Opolski A
Acta Biochim Pol; 2002; 49(1):169-76. PubMed ID: 12136937
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of novel androgen-linked phosphoramide mustard prodrugs and growth-inhibitory activity in human breast cancer cells.
Roth T; Tang W; Eisenbrand G
Anticancer Drug Des; 1995 Dec; 10(8):655-66. PubMed ID: 8595124
[TBL] [Abstract][Full Text] [Related]
5. Acyloxymethyl esters of isophosphoramide mustard as new anticancer prodrugs.
Cytarska J; Misiura K; Filip-Psurska B; Wietrzyk J
Acta Pol Pharm; 2013; 70(3):481-7. PubMed ID: 23757939
[TBL] [Abstract][Full Text] [Related]
6. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
Jain M; Fan J; Baturay NZ; Kwon CH
J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
[TBL] [Abstract][Full Text] [Related]
7. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Roy P; Waxman DJ
Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
[TBL] [Abstract][Full Text] [Related]
8. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide.
Struck RF; Schmid SM; Waud WR
Cancer Chemother Pharmacol; 1994; 34(3):191-6. PubMed ID: 8004750
[TBL] [Abstract][Full Text] [Related]
10. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
[TBL] [Abstract][Full Text] [Related]
11. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
Struck RF; Dykes DJ; Corbett TH; Suling WJ; Trader MW
Br J Cancer; 1983 Jan; 47(1):15-26. PubMed ID: 6821629
[TBL] [Abstract][Full Text] [Related]
12. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Lehouritis P; Marais R; Springer CJ
J Med Chem; 2003 Apr; 46(9):1690-705. PubMed ID: 12699387
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
[TBL] [Abstract][Full Text] [Related]
14. Peptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA).
Jiang Y; Hu L
Bioorg Med Chem; 2013 Dec; 21(23):7507-14. PubMed ID: 24139844
[TBL] [Abstract][Full Text] [Related]
15. 1,3- vs 1,5-intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards.
Springer JB; Chang YH; Koo KI; Colvin OM; Colvin ME; Dolan ME; Delaney SM; Flowers JL; Ludeman SM
Chem Res Toxicol; 2004 Sep; 17(9):1217-26. PubMed ID: 15377155
[TBL] [Abstract][Full Text] [Related]
16. Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept.
Skarbek C; Lesueur LL; Chapuis H; Deroussent A; Pioche Durieu C; Daville A; Caron J; Rivard M; Martens T; Bertrand JR; Le Cam E; Vassal G; Couvreur P; Desmaele D; Paci A
J Med Chem; 2015 Jan; 58(2):705-17. PubMed ID: 25494842
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
18. Intensely cytotoxic anthracycline prodrugs: galactosides.
Bakina E; Farquhar D
Anticancer Drug Des; 1999 Dec; 14(6):507-15. PubMed ID: 10834272
[TBL] [Abstract][Full Text] [Related]
19. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
[TBL] [Abstract][Full Text] [Related]
20. Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide.
Germann N; Urien S; Rodgers AH; Ratterree M; Struck RF; Waud WR; Serota DG; Bastian G; Jursic BS; Morgan LR
Cancer Chemother Pharmacol; 2005 Feb; 55(2):143-51. PubMed ID: 15592722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]